Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Denali Therapeutics Inc (NQ: DNLI)
18.26 USD  +0.08 (+0.44%)
Official Closing Price  /  Updated: 4:00 PM EST, Dec 6, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 317,110
Open 18.26
Bid (Size) 17.90 (3)
Ask (Size) 18.50 (2)
Prev. Close 18.18
Today's Range 17.97 - 18.57
52wk Range 14.24 - 28.86
Shares Outstanding 94,441,892
Dividend Yield N/A
Performance
YTD
-5.54%
-5.54%
1 Month
+10.50%
+10.50%
3 Month
+1.67%
+1.67%
6 Month
-1.30%
-1.30%
1 Year
-3.59%
-3.59%
Top News
More News
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award
Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that... Read More
from PR Newswire
Torque Presents Preclinical Data for Lead Deep-Primed Cellular Immunotherapy Programs at AACR 2019 Special Conference on Tumor Immunology and Immunotherapy
Torque, a clinical-stage immuno-oncology company developing Deep Primed™ T cell immunotherapy to direct immune power deep within the tumor microenvironment, announced today additional preclinical data... Read More
from PR Newswire
More News
Read More
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer
from PR Newswire
Torque Presents New Preclinical Data for Three Deep-Primed Cellular Immunotherapy Programs, Including Newly Unveiled Deep TLR, at SITC 2019 Meeting
from PR Newswire
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
from GlobeNewswire News Releases
Flagship Pioneering Unveils Cygnal Therapeutics
from PR Newswire
Torque Therapeutics Announces the Appointment of John Cox as Chief Executive Officer
from Business Wire News Releases
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website
from GlobeNewswire News Releases
Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer
from Business Wire News Releases
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
from GlobeNewswire News Releases
2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now
category SNY , DNLI , BIIB , and 4 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.